YCYung-Yi Chen

Yung-Yi Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yung-Yi Chen has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Ezekwe Amirize

    Scar Free Foundation Centre for Conflict Wound Research, University Hospital Birmingham, Birmingham, UK

    5 shared publications
  • Yvonne Wilson

    Scar Free Foundation Centre for Conflict Wound Research, University Hospital Birmingham, Birmingham, UK

    5 shared publications
  • Janet Margaret Lord

    Department of Inflammation and Ageing, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham B15 2TT, UK

    4 shared publications
  • Abdulrazak Abdulsalam

    Scar Free Foundation Centre for Conflict Wound Research, University Hospital Birmingham, Birmingham, UK

    3 shared publications
  • Amberley Prince

    Burns Research Centre, University Hospital Birmingham, Birmingham, UK

    3 shared publications
  • Claudia Roberts

    University Hospitals Birmingham NHS Foundation Trust, Heartlands Hospital, Birmingham, UK

    3 shared publications

Latest Publications

  • Open Access

    Cellular heterogeneity in hypertrophic burn scars in response to carbon dioxide laser therapy

    by Yung-Yi Chen, Christopher Mahony, Jason Turner, Charlotte G. Smith, Abdulrazak Abdulsalam, Ezekwe Amirize, Amberley Prince, Adrian Heagerty, Claudia Roberts, Adam Croft, et al.

    Ablative fractional carbon dioxide (AFCO2) laser therapy is used for treating pathological scarring. However, mechanisms underlying reduction in hypertrophic scarring are poorly understood. We investigated cellular mechanisms of AFCO2 laser therapy by performing single-cell RNA sequencing (scRNA-seq) on skin biopsies from burn survivors with hypertrophic scars before and after three sessions of AFCO2 therapy. Scar reduction was assessed subjectively and objectively. Those with a good response (GR) to laser therapy have scars less than 6 years from injury, whereas poor responders (PR) have scars over 6 years since injury. ScRNA-seq analysis of skin biopsies reveals that genes enriched in GR are associated with extracellular matrix and structure organisation (COL14A1, POSTN, SPARC); whereas genes enriched in PR are related to enhanced immune inflammatory responses (CXCL14, JUN, TNC). Notably, expression of the pro-fibrotic gene Engrailed-1 (EN1) remains elevated in PR scars compared to GR. The ECM-regulatory gene TIMP-1 (Tissue Inhibitor of Metalloproteinases 1) is also significantly upregulated in PR scars following treatment relative to GR scars, although at the protein level TIMP1 levels decrease in PR but increase in GR after therapy. The regenerative-associated gene, TRPS1 (Transcriptional Repressor GATA Binding 1) expression demonstrates opposing regulation post treatment, with upregulation observed in GR scars but downregulation in PR scars, underscoring distinct transcriptional trajectories associated with differential therapeutic outcomes. Finally, distinct intercellular communication networks and differentiation trajectories are observed after AFCO2, with regenerative mesenchymal fibroblasts predominating in GR but inflammatory fibroblasts associated with PR. We conclude AFCO2 laser therapy is more effective if done early after injury and distinct fibroblast recruitment is associated with a good response, specifically regenerative fibroblasts.


  • Open Access

    Cellular heterogeneity in hypertrophic burn scars in response to carbon dioxide laser therapy

    by Janet Lord, Yung-Yi Chen, Christopher Mahony, Jason Turner, Charlotte Smith, Abdulrazak Abdulsalam, Ezekwe Amirize, Amberley Prince, Adrian Heagerty, Claudia Roberts, et al.

    Ablative fractional carbon dioxide (AFCO2) laser therapy is widely used for treating pathological scarring, with promising clinical results. However, mechanisms underlying reduction hypertrophic scarring are poorly understood. We investigated the cellular mechanisms of AFCO2 laser therapy by performing single-cell RNA sequencing (scRNA-seq) on skin biopsies from burn survivors with hypertrophic scars before and after AFCO2 therapy. Those with a good response (GR) to laser therapy, assessed objectively and subjectively, generally had scars less than 6 years from injury, whereas poor responders (PR) had more mature scars over 6 years since injury. Additionally, scRNA-seq analysis revealed that genes enriched in GR were associated with extracellular matrix and structure organisation (COL14A1, POSTN, SPARC); whereas genes enriched in PR were related to enhanced immune inflammatory responses (CXCL14, JUN, TNC). Distinct intercellular communication networks and differentiation trajectories were observed after AFCO2, with regenerative mesenchymal fibroblasts predominating in GR but inflammatory fibroblasts associated with PR.

  • Open Access

    Cellular heterogeneity in hypertrophic burn scars in response to carbon dioxide laser therapy

    by Yung-Yi Chen, Christopher Mahony, Jason Turner, Charlotte M Smith, Abdulrazak Abdulsalam, Ezekwe Amirize, Amberley Prince, Adrian Heagerty, Claudia Roberts, Adam Croft, et al.

    Fractional carbon dioxide (AFCO 2 ) laser therapy is used for treating pathological scarring, but the clinical outcomes are variable and the mechanisms of scar reduction poorly understood. We investigated the mechanisms underpinning efficacy of AFCO 2 laser therapy, performing single-cell RNA sequencing in skin biopsies from patients with hypertrophic scars after AFCO 2 laser therapy. Patients with younger scars (Good Responder, GR, 6 years from healing) by various measures of scarring. scRNAseq analysis revealed that genes enriched in GR were associated with extracellular matrix and structure organisation ( COL14A1 , POSTN , SPARC ); whereas genes enriched in PR were related to enhanced immune responses ( IL-12 , MSTN, HLA-DQA ). The groups had distinct intercellular communication networks and differentiation trajectories after AFCO 2 , with regenerative Mesenchymal fibroblasts associated with a good response and inflammatory Secretory Papillary and Inflammatory Fibroblasts with a poor response.

  • Open Access

    Vascular adhesion protein-1 blockade in primary sclerosing cholangitis: Open-label, multicenter, single-arm, phase II trial

    by Gideon M. Hirschfield, Katherine Arndtz, Amanda Kirkham, Yung-Yi Chen, Richard Fox, Anna Rowe, Jessica Douglas-Pugh, Douglas Thorburn, Eleanor Barnes, Guruprasad P. Aithal, et al.

    Background: Primary sclerosing cholangitis is a progressive inflammatory liver disease characterized by biliary and liver fibrosis. Vascular adhesion protein-1 (VAP-1) is important in the inflammatory process driving liver fibrosis. We evaluated the safety and efficacy of VAP-1 blockade with a monoclonal antibody (timolumab, BTT1023) in patients with primary sclerosing cholangitis. Methods: BUTEO was a prospective, single-arm, open-label, multicenter, phase II trial, conducted in 6 centers in the United Kingdom. Patients with primary sclerosing cholangitis aged 18–75 years had an alkaline phosphatase value of >1.5 times the upper limit of normal. The dose-confirmatory stage aimed to confirm the safety of timolumab through the incidence of dose-limiting toxicity and sufficient trough levels of circulating antibody to block VAP-1 function. The primary outcome of the dose-expansion portion of the trial was patient’s response to timolumab at day 99, as measured by a reduction in serum alkaline phosphatase by 25% or more from baseline to day 99. Results: Twenty-three patients were recruited: 7 into the initial dose-confirmatory stage and a further 16 into an expansion stage. Timolumab (8 mg/kg) was confirmed to be safe for the duration of administration with sufficient circulating levels. Only 2 of the 18 evaluable patients (11.1%) achieved a reduction in alkaline phosphatase levels of 25% or more, and both the proportion of circulating inflammatory cell populations and biomarkers of fibrosis remained unchanged from baseline. Conclusions: The BUTEO trial confirmed 8 mg/kg timolumab had no short-term safety signals and resulted in sufficient circulating levels of VAP-1 blocking timolumab. However, the trial was stopped after an interim assessment due to a lack of efficacy as determined by no significant change in serum liver tests.


  • Open Access

    Influence of scar age, laser type and laser treatment intervals on paediatric burn scars: a systematic review and meta-analysis

    by Yangmyung Ma, Sabrina P Barnes, Yung-Yi Chen, Naiem Moiemen, Janet M Lord, Amanda V Sardeli

    Laser therapy has emerged to play a valuable role in the treatment of paediatric burn scars; however, there is heterogeneity in the literature, particularly concerning optimal timing for initiation of laser therapy. This study aims to investigate the effect of factors such as scar age, type of laser and laser treatment interval on burn scar outcomes in children by meta-analysis of previous studies. A literature search was conducted across seven databases in May 2022 to understand the effects of laser therapy on burn scar outcomes in paediatric patients by metanalysis of standardized mean difference (SMD) between pre- and post-laser intervention. Meta-analyses were performed using the Comprehensive Meta-Analysis software version 4.0. Fixed models were selected when there was no significant heterogeneity, and the random effects model was selected for analysis when significant heterogeneity was identified. For all analyses, a p-value < 0.05 was considered significant. Seven studies were included in the meta-analysis with a total of 467 patients. Laser therapy significantly improved Vancouver Scar Scale (VSS)/Total Patient and Observer Scar Assessment Scale (Total POSAS), vascularity, pliability, pigmentation and scar height of burn scars. Significant heterogeneity was found between the studies and thus subgroup analyses were performed. Early laser therapy (12 months post-injury) {SMD −1.97 [95% confidence interval (CI) = −3.08; −0.87], p < 0.001 vs −0.59 [95%CI = −1.10; −0.07], p = 0.03} as well as vascularity {SMD −3.95 [95%CI = −4.38; −3.53], p < 0.001 vs −0.48 [95%CI = −0.66; −0.30], p < 0.001}. Non-ablative laser was most effective, significantly reducing VSS/POSAS, vascularity, pliability and scar height outcomes compared to ablative, pulse dye laser and a combination of ablative and pulse dye laser. Shorter treatment intervals of <4 weeks significantly reduced VSS/POSAS and scar height outcomes compared to intervals of 4 to 6 weeks. Efficacy of laser therapy in the paediatric population is influenced by scar age, type of laser and interval between laser therapy application. The result of this study particularly challenges the currently accepted initiation time for laser treatment. Significant heterogeneity was observed within the studies, which suggests the need to explore other confounding factors influencing burn scar outcomes after laser therapy.


  • Open Access

    SMOOTH protocol: A pilot randomised prospective intra-patient single-blinded observational study for examining the mechanistic basis of ablative fractional carbon dioxide laser therapy in treating hypertrophic scarring

    by Yung-Yi Chen, Krupali M. Patel, Rizwana Imran, Tarek Hassouna, Ezekwe Amirize, Abdulrazak Abdulsalam, Jonathan Bishop, Anita Slade, Maximina Ventura, Jeremy Yarrow, et al.

    Background: Burn injuries are the fourth most common type of trauma and are associated with substantial morbidity and mortality. The impact of burn injury is clinically significant as burn injuries often give rise to exuberant scarring. Hypertrophic scarring (HTS) is a particular concern as up to 70% of burns patients develop HTS. Laser therapy is used for treating HTS and has shown positive clinical outcomes, although the mechanisms remain unclear limiting approaches to improve its effectiveness. Emerging evidence has shown that fibroblasts and senescent cells are important modifiers of scarring. This study aims to investigate the cellular kinetics in HTS after laser therapy, with a focus on the association of scar reduction with the presence of senescent cells. Methods: We will conduct a multicentre, intra-patient, single-blinded, randomised controlled longitudinal pilot study with parallel assignments to achieve this objective. 60 participants will be recruited to receive 3 interventional ablative fractional CO2 laser treatments over a 12-month period. Each participant will have two scars randomly allocated to receive either laser treatment or standard care. Biopsies will be obtained from laser-treated, scarred-no treatment and non-scarred tissues for immune-histological staining to investigate the longitudinal kinetics of p16INK4A+-senescent cells and fibroblast subpopulations (CD90+/Thy1+ and αSMA+). Combined subjective scar assessments including Modified Vancouver Scar Scale, Patient and Observer Scar Assessment Scale and Brisbane Burn Scar Impact Profile; and objective assessment tools including 3D-Vectra-H1 photography, DermaScan® Cortex, Cutometer® and ColoriMeter®DSMIII will be used to evaluate clinical outcomes. These will then be used to investigate the association between senescent cells and scar reduction after laser therapy. This study will also collect blood samples to explore the systemic biomarkers associated with the response to laser therapy. Discussion: This study will provide an improved understanding of mechanisms potentially mediating scar reduction with laser treatment, which will enable better designs of laser treatment regimens for those living with HTS. Trial registration: ClinicalTrials.gov: NCT04736251.


  • Open Access

    SMOOTH protocol: A pilot randomised prospective intra-patient single-blinded observational study for examining the mechanistic basis of ablative fractional carbon dioxide laser therapy in treating hypertrophic scarring

    by Yung-Yi Chen, Krupali M. Patel, Rizwana Imran, Tarek Hassouna, Ezekwe Amirize, Abdulrazak Abdulsalam, Jonathan Bishop, Anita Slade, Maximina Ventura, Jeremy Yarrow, et al.

    Background: Burn injuries are the fourth most common type of trauma and are associated with substantial morbidity and mortality. The impact of burn injury is clinically significant as burn injuries often give rise to exuberant scarring. Hypertrophic scarring (HTS) is a particular concern as up to 70% of burns patients develop HTS. Laser therapy is used for treating HTS and has shown positive clinical outcomes, although the mechanisms remain unclear limiting approaches to improve its effectiveness. Emerging evidence has shown that fibroblasts and senescent cells are important modifiers of scarring. This study aims to investigate the cellular kinetics in HTS after laser therapy, with a focus on the association of scar reduction with the presence of senescent cells. Methods: We will conduct a multicentre, intra-patient, single-blinded, randomised controlled longitudinal pilot study with parallel assignments to achieve this objective. 60 participants will be recruited to receive 3 interventional ablative fractional CO 2 laser treatments over a 12-month period. Each participant will have two scars randomly allocated to receive either laser treatment or standard care. Biopsies will be obtained from laser-treated, scarred- no treatment and non-scarred tissues for immune-histological staining to investigate the longitudinal kinetics of p16 INK4A+ -senescent cells and fibroblast subpopulations (CD90 + /Thy1 + and αSMA + ). Combined subjective scar assessments including Modified Vancouver Scar Scale, Patient and Observer Scar Assessment Scale and Brisbane Burn Scar Impact Profile; and objective assessment tools including 3D-Vectra-H1 photography, DermaScan ® Cortex, Cutometer ® and ColoriMeter ® DSMIII will be used to evaluate clinical outcomes. These will then be used to investigate the association between senescent cells and scar reduction after laser therapy. This study will also collect blood samples to explore the systemic biomarkers associated with the response to laser therapy. Discussion: This study will provide an improved understanding of mechanisms potentially mediating scar reduction with laser treatment, which will enable better designs of laser treatment regimens for those living with HTS. Trial registration: ClinicalTrials.gov: NCT04736251 .

  • Open Access

    Monoclonal antibody BTT1023 targeting vascular adhesion protein 1 for treating primary sclerosing cholangitis: BUTEO single-arm Phase II trial

    by Katherine Arndtz, Yung-Yi Chen, Anna Rowe, Victoria Homer, Amanda Kirkham, Jessica Douglas-Pugh, Daniel Slade, Douglas Thorburn, Eleanor Barnes, Guruprasad Aithal, et al.

    Background: Primary sclerosing cholangitis is a progressive and fibrotic liver disease. Treatments remain inadequate, and patients with persistent elevations in activity of alkaline phosphatase are at greatest risk of disease progression. Studies in patient cohorts have implicated the serum amine oxidase vascular adhesion protein 1 in the pathophysiology of disease, including liver fibrogenesis. We hypothesised that blockade of serum amine oxidase by a monoclonal antibody would result in a reduction in liver fibrosis/injury, as evaluated by serum liver tests and other non-invasive markers of liver injury. Objectives: To evaluate the open-label effect on liver injury markers of treatment with the anti-vascular adhesion protein 1 monoclonal antibody BTT1023 in patients with primary sclerosing cholangitis over a 78-day treatment period. Design: A single-arm, two-stage, open-label, multicentre, Phase II clinical trial. Setting: Ambulatory liver disease practices in tertiary care hospitals. Participants: Patients with primary sclerosing cholangitis at risk of disease progression, based on elevated activity of serum alkaline phosphatase, and without evidence of infection, liver failure or advanced disease. Intervention: Seven intravenous infusions of BTT1023 (8 mg/kg of timolumab) over a 78-day treatment period. The intervention was split into a dose-confirmatory stage (to confirm pharmacokinetics), followed by a confirmed expansion cohort stage. Main outcome measures: Our primary outcome measure was patient response to treatment at day 99, measured by a reduction in activity of serum alkaline phosphatase of ≥ 25% from baseline to day 99. Secondary markers of efficacy were assessed based on evaluation of changes in markers of liver injury and liver fibrosis. Safety assessments were performed throughout. Results: Thirty-five patients were consented and screened for eligibility. Twenty-three patients were treated across the two stages of the trial. Interim assessment demonstrated a failure to meet the primary end point, leading to trial discontinuation on the grounds of futility. Multiple exploratory markers were evaluated in a final cohort of 22 patients (modified intention-to-treat analysis). No treatment-related effects were evident. No new safety concerns were seen. Conclusions: No preliminary evidence for disease modification was demonstrated. Limitations: It is clear that this study is limited in its design. Even if there were a better biomarker of fibrosis turnover that could be considered the ‘gold standard’, the design and duration would have had real-world resource limitations. With limited opportunity to test a new agent in large numbers of patients over a prolonged period, it was necessary to aim to see efficacy in a small cohort over a short period. Given the absence of any proven biochemical surrogate of disease activity in primary sclerosing cholangitis, alkaline phosphatase was chosen as an end point. This remains a difficult end point (yet one that does capture biliary injury) and, therefore, despite limitations, this study did demonstrate short-term safety. Future work: Future research will require attention to an ongoing debate regarding the optimal end points for assessing efficacy, as well as consideration of duration of treatment, even in early-phase studies. This raises the challenge of how to fund early experimental trials with ‘high risk of failure’ adequately to ensure that clearer results (negative or positive) arise by the end of the study. Trial registration: Current Controlled Trials ISRCTN11233255, EudraCT 2014-002393-37 and NCT02239211. Funding: This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council and National Institute for Health Research (NIHR) partnership. This will be published in full in Efficacy and Mechanism Evaluation; Vol. 9, No. 1. See the NIHR Journals Library website for further project information.